⊖ PRESENTERS

The *6th China Healthcare Summit* will feature Road Show presentations to showcase private and public biotechs from China, Asia and the West. This will be a unique opportunity for companies to present in Shanghai to top China investors and biopharma CEOs, as well as domestic and multinational pharma licensing executives.

Presenting Companies are hand-picked by BioCentury and BayHelix based on rigorous selection criteria, including investor validation, upcoming milestones, unpartnered assets and innovative science.

For information on becoming a Presenting Company, please email Josh Berlin.

- AffaMed Therapeutics
- AnimaBiotech
- APTORUM
- Arecor
- AURANSA
- BeiGene
- BiOncoTech
- bioshin 标新
- BOSTON pharmaceuticals
- Crescendo biologics
- CYTOMX THERAPEUTICS
- DotBio
- Elpiscience
- EOC
- EryDel
- eTheRNA
- GENEMEDICINE
- genenta science
- Happy Life Tech
- HOOKIPA PHARMA
- Hua Medicine
- ImmuneOncia Therapeutics Inc.
- IMPACT Therapeutics
- Insilico Medicine 英科智能
- ISU ABXIS
- LIGHTOX
- LinkDoc Care Data · Care Life
- miracor medical
- mithra Women's Health
- OCTIMET
- OliPass
- Oncologie
- OxfordBioMedica
- PharmAbcine Antibody Therapeutics for Life
- Q3 Medical DEVICES LIMITED
- RETROGENIX
- Sotio
- Summit therapeutics
- Synaffix
- TEMPEST THERAPEUTICS
- TRACON PHARMA
- TRANSCENTA INNOVATE TO EXCEL
- vaccitech
- 依生生物 YISHENG BIOPHARMA
- zai lab
- ZHAOKE OPHTHALMOLOGY

⊖ SPONSORS

The importance of the *China Healthcare Summit* is demonstrated by the commitment from its collaborators and supporting organizations. For information on sponsorship opportunities, please email Josh Berlin at BioCentury.

INSIGHTS PARTNER

McKinsey & Company

CHINA BIOTECH TRACK HOST

BeiGene

GLOBAL BIOTECH TRACK HOST

zaiLab™

U.K. BIOTECH TRACK HOST

BiA

UK BioIndustry Association

KOREA BIOTECH TRACK HOSTS

KDDF Korea Drug Development Fund

BiP FOCUS GLOBAL CONSULTING

BELGIUM BIOTECH TRACK HOSTS

AGIO / capital & business solutions

FLANDERS INVESTMENT & TRADE

Wallonia.be EXPORT INVESTMENT

AI/PRECISION MEDICINE TRACK HOST

Insilico Medicine 英科智能

CEO STRATEGIC BOOT CAMP HOSTS

BRUNSWICK 博然思维

dMed 缔脉

SIDLEY 盛德

TALENTS PARTNER

Russell Reynolds Associates 50 YEARS

SPONSORS

三生制药 3SBIO INC.
AstraZeneca 阿斯利康
Boehringer Ingelheim
Bristol-Myers Squibb
CBC Group

Davis Polk
HEDA
ICT Innovative Cellular Therapeutics
LAKE BLEU
LEE'S PHARM. 李氏大藥廠

罗欣药业 LUOXIN PHARMACEUTICAL
鹏泽资本 LYZZ CAPITAL
MERCK
NAN FUNG LIFE SCIENCES 南豐生命科技
NOMURA

PANACEA VENTURE HEALTHCARE
Panmure Gordon AND COMPANY
PIVOTAL BIOVENTURE PARTNERS 鼎豐生科資本
啓明創投 QIMING VENTURE PARTNERS
QUAN

SANOFI

NETWORKING HOST SPONSORS

CEC CAPITAL
novo nordisk

SUPPORTING ORGANIZATIONS

bioBAY
CHINABIO
GBi
Healthcare Drinks 健谈会
KoreaBio

lingmed 灵麦医药
Lychee Group
PharmaDJ
PhIRDA 中国药促会
RDPAC

PARTNER EVENT

CHIC 启珂健康投资论坛

⊖ SPEAKERS

JEFFREY ALGAZY
Senior Partner
McKinsey & Co.

JUN BAO, PH.D.
President & CEO
Impact Therapeutics

YONG BEN, M.D.
Chief Medical Officer, Immuno-oncology
BeiGene Ltd.

LAURA BENJAMIN, PH.D.
President & CEO
Oncologie Inc.

JOSHUA BERLIN
Executive Director, New Ventures
BioCentury

KAREN BERNSTEIN, PH.D.
Chairman
BioCentury

SEAN CAO, PH.D.
CEO
Everest Medicines

MICHAEL CHAN
Head, International Issuer Services
Hong Kong Exchanges and Clearing Ltd.

HONGMING CHEN, PH.D.
Professor & Principal Investigator
Guangzhou Regenerative Medicine and Health

LANHEE CHEN, PH.D.
Senior Counselor
Brunswick LLP

LI CHEN, PH.D.
Founder & CEO
Hua Medicine Ltd.

TONY CHEN, PH.D.
Chairman, BayHelix and
Partner, Jones Day

YUZHONG CHEN, M.D.
Chief Medical Officer & VP
Airdoc

YONGSHUN CHENG
Director
Beijing Intellectual Property Institute, and former Senior Judge, IP Division, Beijing High People's Court

ALBERTO COLZI
President International, Japan, Emerging Markets & Australia
AbbVie Inc.

DAVID COX, PH.D.
Director, Healthcare
Panmure Gordon and Co.

JOE DAMOND
EVP, International Affairs
BIO (Biotechnology Innovation Organization)

MARTIN DEWHURST
Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice
McKinsey & Co.

MENG DING
Partner
Sidley Austin LLP

THOMAS DUBENSKY, PH.D
President & CEO
Tempest Therapeutics Inc.

RONNIE EDE
CFO
Innovent Biologics Inc.

CARL FIRTH, PH.D.
Founder & CEO
Aslan Pharmaceuticals Ltd.

SIMONE FISHBURN, PH.D.
Editor in Chief
BioCentury

DAVID FLORES
President & CEO
BioCentury

TAO FU
President & COO
Zai Lab

JULIO GAY-GER
President & General Manager, Lilly China
Eli Lilly and Co.

TAO GUO, PH.D.
VP & Head, International Discovery Service Unit
WuXi AppTec

WENYU GUO, M.D.
VP, Clinical Operations
CStone Pharmaceuticals Co. Ltd.

YIMING HAO
General Manager, Innovative Commercialization Solutions
HLT

THEODORA HAROLD
CEO
Crescendo Biologics Ltd.

JAKE HENRY
Senior Partner & Global Co-Lead, Pharmaceuticals & Medical Products Practice
McKinsey & Co.

CHRISTIAN HOGG
Executive Director & CEO
Hutchison China MediTech Ltd.

IRENE HONG
Founding Partner
CEC Capital

PIUS S. HORNSTEIN, PH.D.

Country Chair & General Manager
Sanofi China

in

TINA HOU

Partner, Shanghai
McKinsey & Co.

in

JAMES HUANG

Managing Partner
KPCB China, and Founding Managing Partner, Panacea Venture

in

MIN IRWIN, PH.D.

CEO
Reistone Biopharma Co. Ltd.

in

RUCHUN JI

Partner
Sidley Austin LLP

in

FRANK JIANG, M.D., PH.D.

CEO
CStone Pharmaceuticals

in

KEWEN JIN, M.D.

Managing Partner
Serica Capital

in

HENK JOOS, PH.D.

General Manager
Agio Capital & Business Solutions

in

WEI KANG

VP, Strategic Consulting
AUSTAR Group

in

WEI KANG

Managing Director
RDPAC (R&D-Based Pharmaceutical Association Committee)

in

VIJAY P. KARWAL

Managing Director, Head of Healthcare Investment Banking, Asia ex-Japan
Nomura

in

FABIO LANDAZABAL

Senior Vice President & Head of Pharmaceuticals, Emerging Markets and General Manager, China Pharmaceutical
GlaxoSmithKline plc

in

GUIDO LANZA

CEO
Numerate Inc.

in

FRANCK LE DEU

Senior Partner & Head of Greater China Healthcare Practice
McKinsey & Co.

in

NISA LEUNG

Managing Partner
Qiming Venture Partners

in

BIN LI, PH.D.

CIO and CEO
Lake Bleu Capital

DERRICK LI

Head of Strategy & Investor Relations
Cellular Biomedicine Group

HELEN QINGHONG LI, M.D.

Head, Medical Quality Assurance, China
Pfizer Inc.

JIN LI, PH.D.

Chairman & CEO
HitGen Ltd.

JUDITH LI

Partner
Lilly Asia Ventures

KEVIN LI, PH.D.

Co-Founder & Managing Partner
LYZZ Capital

NING LI, PH.D.

Executive Director, CEO & GM
Shanghai Junshi Biosciences Co. Ltd.

JAMES LIN

Partner
Davis Polk

DA LIU

Managing Director
CR-CP Life Science Fund

LIPING LIU, PH.D.

Founder, CEO & Chief Scientific Officer
HighTide Therapeutics Inc.

YI LIU

VP, Clinical Science & Medical Affairs
dMed Biopharmaceutical Co. Ltd.

JOSEPH CHI-LUN LO

Partner
Brunswick Group LLP

CHRIS LU, PH.D.

Founder & CEO
Laekna Therapeutics Shanghai Co. Ltd.

HONGTAO LU, PH.D.

Co-Founder, Chief Scientific Officer & Director
Elpiscience Biopharmaceuticals Co. Ltd.

PONY LU

CEO
Visen Pharmaceuticals

XIANPING LU, PH.D.
Founder & CEO
Shenzhen Chipscreen Biosciences Ltd.

PEK LUM, PH.D.
Co-founder and CEO
Auransa Inc.

JAMES MENDENHALL
Partner
Sidley Austin LLP and former General Counsel, Office of the United States Trade Representative

LUKE MIELS
President, Global Pharmaceuticals
GSK

ST. JOHN MOORE
Partner & Head of Beijing
Brunswick Group LLP

AI HUA ONG
Company Group Chairman
Janssen Asia Pacific

STEVEN POWELL, PH.D.
CEO
eTheRNA immunotherapies N.V.

DIANNA QIAN
Partner
Pivotal Bioventure China

DONGXU QIU, PH.D.
Co-Founder & Executive VP, Strategy and Business Development
CanSino Biologics Inc.

RANDALL RADER
Principal
The Radar Group, and former Chief Judge, U.S. Court of Appeals for the Federal Circuit

B.G. RHEE
CEO
SCM Life Sciences, and Chairman, Council for Advanced Regenerative Medicine

JOSEPH ROMANELLI
President, MSD China
Merck & Co. Inc.

GRAZIANO SEGHEZZI
Managing Partner
Sofinnova Partners

KRISTINE SENFT
VP Global Business Development & Key Account Management
Boehringer Ingelheim Biopharmaceuticals GmbH

JOAN SHEN, M.D., PH.D.
CEO
I-Mab Biopharma Co. Ltd.

JUN SHI, M.D.
SVP, Early Development & Clinical Pharmacology
dMed Biopharmaceutical Co. Ltd.

VICTOR SHI, PH.D.
CEO
Adicon Clinical Laboratories

RUILIN SONG
Executive President
PhIRDA (China Pharmaceutical Innovation and Research Development Association)

SOPHIE SUN
Managing Director, Innovation Hub China & VP, Strategy and Transformation, China
Merck Holding (China) Co. Ltd.

LINGSHI TAN, PH.D.
Founder & CEO
dMed Biopharmaceutical Co. Ltd.

LEI XIAO, PH.D.
Chairman, CEO & Chief Scientific Officer
Innovative Cellular Therapeutics Co. Ltd.

STELLA XU, PH.D.
Managing Director
Quan Capital

ANGELA YAN
SVP, Regulatory Affairs & Strategy
dMed Biopharmaceutical Co. Ltd.

STEVE YANG, PH.D.
Co-CEO, Head of RSD, & Head of WuXi Testing
WuXi Apptec

BART VAN HOOLAND
Founding Partner
DROIA Oncology Ventures

PENNY WAN
VP & Regional General Manager, JAPAC
Amgen Inc.

GARY WANG
VP, Human Resources, APAC & Co-Lead Global HR
BeiGene Ltd.

LEON WANG
EVP, International Region & China President
AstraZeneca

YONGZHONG WANG, PH.D.
CEO
CMAB BioPharma Ltd.

ZAIQI WANG, PH.D.
Founder & CEO
InxMed Shanghai

LEWIS T. RUSTY WILLIAMS, PH.D.
Venture Partner
Quan Capital

ANDREW WONG
VP, Transactions Asia Pacific
Johnson & Johnson Innovation

CHENGBIN WU, PH.D.
Founder & CEO
EpimAb Biotherapeutics Inc.

JINZI WU, PH.D.
Founder, Chairman & CEO
Ascletis Pharma Inc.

XIAOBIN WU, PH.D.
General Manager of China & President
BeiGene Ltd.

TINA XU
VP, China Digital & Commercial Innovation
AstraZeneca plc

DAJUN YANG, M.D., PH.D.
Chairman & CEO
Ascentage Pharma

PEIYNG YAO
Executive Director, Quality Assurance
dMed Biopharmaceutical Co. Ltd.

ZHOU YI
Director
Brunswick Group LLP

DEBRA YU, M.D.
President & Chief Business Officer
LianBio

GUO-LIANG YU, PH.D.
CEO & Co-founder
Apollomics Inc.

ERIC ZHANG, PH.D.
VP, Regulatory Affairs & Strategy
dMed Biopharmaceutical Co. Ltd.

FRANK ZHANG, PH.D.
CEO
GenScript Biotech Corp., and Chairman, Legend Biotech

PETER ZHANG
Executive Director
Russell Reynolds Associates

TONY ZHANG
Founder & CEO
LinkDoc Technology (Beijing) Co.

WEIYI ZHANG
Director, External Innovation China
Boehringer Ingelheim GmbH

JONATHAN ZHAO, PH.D.
co-founder & Executive Chairman
Transcenta Holding Ltd.

ALEX ZHAVORONKOV, PH.D.
CEO
Insilico Medicine Inc.

JOHN ZHU, PH.D.
Partner
6 Dimensions Capital

ZHENPING ZHU, PH.D.
President of R&D and Chief Scientific Officer
3SBio Inc.

HAO ZOU, PH.D.
CEO
Tsimage Technology, and Director, Center for Medical Imaging and Health, Tsinghua University

⊖ ORGANIZING COMMITTEE

JUN BAO, PH.D.
President & CEO
Impact Therapeutics

YONG BEN, M.D.
Chief Medical Officer, Immuno-oncology
BeiGene Ltd.

JOSHUA BERLIN
Executive Director, New Ventures
BioCentury

KAREN BERNSTEIN, PH.D.
Chairman
BioCentury

TONY CHEN, PH.D.
Chairman, BayHelix and
Partner, Jones Day

SIMONE FISHBURN, PH.D.
Editor in Chief
BioCentury

DAVID FLORES
President & CEO
BioCentury

LIN SUN-HOFFMAN PH.D., J.D.
Partner
Liu, Zheng, Chen & Hoffman LLP

KEWEN JIN, M.D.
Managing Partner
Serica Capital

FRANCK LE DEU
Senior Partner & Head of Greater China Healthcare Practice
McKinsey & Co.

BIN LI, PH.D.
CIO and CEO
Lake Bleu Capital

JON LIONG
Managing Partner
Lychee Group

WENDY PAN, PH.D.
Partner
Goodwin Procter

VICTOR SHI, PH.D.
CEO
Adicon Clinical Laboratories

STEVE YANG, PH.D.
Co-CEO, Head of RSD, & Head of WuXi Testing
WuXi Apptec

DEBRA YU, M.D.
President & Chief Business Officer
LianBio

DAN ZHANG, M.D.
Chairman
Fountain Medical Development Ltd.

JIMMY ZHANG, PH.D.
Venture Partner
Lilly Asia Ventures

WEI ZHANG, PH.D., M.D.
SVP & Chief Strategy Officer
WuXi AppTec

AWARD WINNERS

For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. This year, BayHelix and BioCentury jointly hosted the 6th China Healthcare Summit (November 18-20, Shanghai), and presented the awards in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.

CHINA HEALTHCARE SUMMIT 2019

R&D Achievement of the Year | FibroGen Inc.

Recognizing a scientific discovery in China with direct impact to drug and/or MedTech R&D or a significant achievement in pharmaceutical and/or MedTech development milestones.

For its HIF-PH Inhibitors platform technology and Roxadustat, which is a global first-in-class novel medicine that was first approved in China in December 2018 before anywhere else in the world. HIF-PH and its oxygen sensing research by three scientists won the 2019 Nobel Prize in Physiology or Medicine.

CHINA HEALTHCARE SUMMIT 2019

Deal of the Year | BeiGene Ltd. - Amgen Inc.

Recognizing a groundbreaking pharmaceutical and/or MedTech fund-raising, collaboration, technology transfer, licensing, M&A or joint venture that involves a Chinese entity, either within China or cross-border.

A strategic collaboration that adds nearly two dozen oncology compounds to BeiGene's marketed portfolio and R&D pipeline, and sees Amgen take a 20.5% stake in BeiGene for $2.7B.

CHINA HEALTHCARE SUMMIT 2019

Commercial Achievement of the Year | Zai Lab Ltd.

Recognizing a creative model that delivered superior value to patients/payers in China and commercial success.

Launch of Zejula niraparib in Hong Kong and Macau is a first for Zai Lab, representing its transition into a fully integrated biotech.

CHINA HEALTHCARE SUMMIT 2019

Company of the Year | BioBay

Recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China's pharmaceutical, MedTech and/or healthcare industry.

For developing a world-class biomedical park and innovation ecosystem in Suzhou for life sciences companies, including many leading China biotechs and MedTechs, and MNCs.

CHINA HEALTHCARE SUMMIT 2019

Person of the Year | Dr. Xianping LU

Recognizing an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem for drug and/or MedTech R&D, deal transactions, and/or commercialization etc. in China.

As Chairman & GM of Shenzhen Chipscreen Biosciences Ltd., Xianping has built from scratch a leading innovative China biotech over 18 years, launching lead compound Chidamine tucidinostat in 2014, and in 2019 becoming the first biopharma to IPO on the Shanghai Stock Exchange STAR market.